Biotech - Spark Newswire

2 minute read

Alpha Tau Announces Grant Of Expanded Radioactive License And Final Pre-Clinical Laboratory Regulatory Approval At Its Jerusalem Headquarters

Today, 7:51 AM

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli

DRTS

1 minute read

Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score

By Benzinga Newsdesk

Today, 7:51 AM

Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal

PRAX

1 minute read

Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use

By Benzinga Newsdesk

Today, 7:51 AM

Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation

CTLT

1 minute read

The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia

By Benzinga Newsdesk

Today, 7:51 AM

The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were

BMY

1 minute read

Verve Therapeutics Reported New Preclinical Data In Non-human Primates Demonstrating Potent, Durable, And Well-tolerated Editing Of The ANGPTL3 Gene Following The Administration Of VERVE-201

By Benzinga Newsdesk

Today, 7:51 AM

VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH including the requirement for multiple oral, injectable, and intravenous infusions in each patient, often administered over

VERV

1 minute read

Exelixis’ Phase 3 CONTACT-03 Study Did Not Meet Its Primary Endpoint Of Progression-Free Survival; Shares Fall

By Benzinga Newsdesk

Today, 7:51 AM

CONTACT-03 evaluated cabozantinib plus atezolizumab versus cabozantinib for locally advanced or metastatic clear cell or non-clear cell (papillary or unclassified only) renal cell carcinoma (RCC) who progressed during

EXEL

1 minute read

Reported Late Thursday, March 2, Terns Pharmaceuticals’ Program Updates; Q3 Adjusted Cash Balance As Of Sept 30, 2022, Of $293M Provides Cash Runway Into 2026

By Benzinga Newsdesk

Today, 7:51 AM

Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in the third quarter of 2023 On track to initiate U.S. clinical trial

TERN

1 minute read

Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program

By Vandana Singh

Today, 7:51 AM

As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…

AZN

3 minute read

Cue Health Collaborates With Pfizer To Provide People Who Test Positive For COVID-19 With Actionable Health Information To Better Inform their Treatment Journey

By Happy Mohamed

Today, 7:51 AM

New educational resources will make it easier for people at high risk of progression to severe COVID-19 to protect their health through accessible and timely health information Cue Health ("Cue")

HLTH

2 minute read

Galectin Therapeutics Provides Final Randomization Status Of NAVIGATE, Its Seamless, Adaptive Phase 2b/3 Study of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis

By Happy Mohamed

Today, 7:51 AM

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its

GALT